| An earlier diagnosis
Traditional Alzheimer’s diagnosis has long relied on cognitive assessments and clinical symptoms, often leading to diagnosis well after significant neurodegeneration has occurred. Biomarkers are changing that. A growing body of evidence supports the use of key biomarkers, including amyloid-beta and tau proteins, as sensitive and specific indicators of Alzheimer’s pathology, considering that the changes often begin before symptoms appear. Biomarker tests can detect these proteins very early in the disease and have been shown to improve diagnostic accuracy significantly. That shift is critical: early detection opens the door to timely interventions, e.g., lifestyle changes, access to treatment, and research participation. Personalized care
Much like advances seen in precision oncology, Alzheimer’s care is entering an era of precision medicine. Biomarker tests’ ability to detect multiple pathologies co-existing in Alzheimer’s not only enable early diagnosis, but could guide personalized therapeutic decisions. Staying ahead of the curve
As blood-based biomarkers (BBBMs) gain FDA clearances and public attention, it’s critical for the medical community to focus on the scientific rigor, clinical utility, and appropriate use of these tools. While blood-based tests hold tremendous promise for broadening access, CSF and imaging (i.e., amyloid PET scans) remain the more specific modalities and will likely be needed for some patients for the foreseeable future. As research continues across CSF, PET, and blood-based biomarkers, the goal remains to improve early, accurate diagnosis and disease monitoring. The FDA clearance of blood tests is a significant step forward. Growing availability of these types of tests helps to expand access to testing and supports clinicians across primary and specialty care settings as they navigate this rapidly transforming field. — By MedCity Influencer Maria-Magdalena Patru |
No comments